• LAST PRICE
    4.9099
  • TODAY'S CHANGE (%)
    Trending Up0.3299 (7.2031%)
  • Bid / Lots
    4.5900/ 2
  • Ask / Lots
    4.9400/ 5
  • Open / Previous Close
    4.4700 / 4.5800
  • Day Range
    Low 4.4445
    High 4.9499
  • 52 Week Range
    Low 2.9000
    High 18.9140
  • Volume
    38,942
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 4.58
TimeVolumeBJDX
09:32 ET27264.89
09:34 ET2004.87
09:36 ET11004.59
09:38 ET15914.75
09:39 ET19934.625
09:41 ET28014.78
09:43 ET11454.6201
09:45 ET1004.77
09:48 ET9354.8
09:50 ET16004.6301
09:52 ET17304.76
09:54 ET165474.7955
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBJDX
Bluejay Diagnostics Inc
5.7M
-0.5x
---
United StatesDROR
Dror Ortho-Design Inc
5.7M
0.0x
---
United StatesARTH
Arch Therapeutics Inc
5.1M
-0.3x
---
United StatesSTSS
Sharps Technology Inc
6.5M
-0.8x
---
United StatesBNKL
Bionik Laboratories Corp
6.2M
-0.7x
---
United StatesFEMY
Femasys Inc
4.7M
-0.4x
---
As of 2023-09-25

Company Information

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a near-patient testing system for triage and monitoring of disease progression. The Company's Symphony platform is a technology platform that provides measurements of key diagnostic biomarkers found in whole blood. The Symphony analyzer orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The Company's first product candidate, an IL-6 test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices (IVDs) market, including sepsis, cardio-metabolic diseases, cancer, and other diseases that require rapid tests.

Contact Information

Headquarters
360 Massachusetts Avenue, Suite 203ACTON, MA, United States 01720
Phone
978-631-0152
Fax
302-636-5454

Executives

Independent Chairman of the Board
Douglas Wurth
President, Chief Executive Officer, Co-Founder, Director
Neil Dey
Chief Financial Officer
Kenneth Fisher
Chief Technology Officer
Jason Cook
Director
Svetlana Dey

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.7M
Revenue (TTM)
$0.00
Shares Outstanding
1.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-10.54
Book Value
$11.42
P/E Ratio
-0.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.